Immune Checkpoint Blockade in Malignant Mesothelioma

Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient anti-tumor immune response by targeting regulatory immune checkpoint(s) with immunomodulatory monoclonal antibodies (mAbs), is leading to very promising clinical results in different tumor types. Herein, we highlight the clinical impact so far identified for these new immunomodulatory agents in MM patients and discuss their prospective use to design novel clinical trials.

[Article continues at original source]

Source: Immune Checkpoint Blockade in Malignant Mesothelioma – Seminars in Oncology


 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

 

Speak Your Mind

*

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
Tel: (800) 426-9535
Email@LambLawOffice.com
Disclaimer and Copyright